Boehringer Ingelheim To Break Into Biologics Contract Manufacturing Market In China
This article was originally published in PharmAsia News
Executive Summary
Reporting 32% growth in China for 2012, BI will be the first Big Pharma to enter the biologics contract manufacturing space in the country.